| Literature DB >> 28708997 |
Justin M Richner1, Brett W Jagger1, Chao Shan2, Camila R Fontes2, Kimberly A Dowd3, Bin Cao4, Sunny Himansu5, Elizabeth A Caine1, Bruno T D Nunes6, Daniele B A Medeiros6, Antonio E Muruato7, Bryant M Foreman3, Huanle Luo8, Tian Wang9, Alan D Barrett10, Scott C Weaver11, Pedro F C Vasconcelos12, Shannan L Rossi13, Giuseppe Ciaramella5, Indira U Mysorekar14, Theodore C Pierson15, Pei-Yong Shi16, Michael S Diamond17.
Abstract
The emergence of Zika virus (ZIKV) and its association with congenital malformations has prompted the rapid development of vaccines. Although efficacy with multiple viral vaccine platforms has been established in animals, no study has addressed protection during pregnancy. We tested in mice two vaccine platforms, a lipid nanoparticle-encapsulated modified mRNA vaccine encoding ZIKV prM and E genes and a live-attenuated ZIKV strain encoding an NS1 protein without glycosylation, for their ability to protect against transmission to the fetus. Vaccinated dams challenged with a heterologous ZIKV strain at embryo day 6 (E6) and evaluated at E13 showed markedly diminished levels of viral RNA in maternal, placental, and fetal tissues, which resulted in protection against placental damage and fetal demise. As modified mRNA and live-attenuated vaccine platforms can restrict in utero transmission of ZIKV in mice, their further development in humans to prevent congenital ZIKV syndrome is warranted.Entities:
Keywords: Vaccine; antibody; fetus; flavivirus; immunity; microcephaly; pregnancy; transmission
Mesh：
Substances：
Year: 2017 PMID： 28708997 PMCID： PMC5546158 DOI： 10.1016/j.cell.2017.06.040
Source DB: PubMed Journal: Cell ISSN： 0092-8674 Impact factor: 41.582